Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2326

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 4
Chunk 2326
---
 conversions

    (2,508,000
    )

    -

    -

    Deemed dividend – warrant repricing

    (276,839
    )

    -

    -

    Net loss attributable to common shareholders 
     
    $
    (10,517,051
    )
     
    $
    (572,211
    )
     
    $
    (7,289,577
    )

    Net loss per common share: 

    Basic and diluted 
    $(18.15)
    $(97.90) 
    $(1,248.64)
  
    Weighted average common shares outstanding: 

    Basic and diluted 
     579,432 
     5,845  
     5,838 

See accompanying notes
to the consolidated financial statements

Reflects a 1-for-100 reverse stock split effective
January 8, 2025

F-4

CERO THERAPEUTICS HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED
STOCK AND 
STOCKHOLDERS’ DEFICIT

    Convertible
    Preferred Stock  

    Additional  
    Stock  
       
    Total 

    Series
    A  
    Series
    B  
    Series
    C  
    Series
    A Common Stock  
    Paid-in  
    Subscriptions  
    Accumulated  
    Stockholders’ 

    Shares  
    Amount  
    Shares  
    Amount  
    Shares  
    Amount  
    Shares  
    Amount  
    Capital  
    Receivable  
    Deficit  
    Deficit 

    Balance
    at 2/14/2024 (Successor) 
     10,089  
    $8,937,852  
     -  
    $-  
     -  
    $     -  
     145,318  
    $15  
    $53,899,871  
    $(2,000,000) 
    $(63,185,641) 
    $(2,347,903)
  
    Issuance
of shares of Series A Preferred Stock upon exercise of Series A Preferred Warrants, net of issuance costs of $14,693 
     1,875  
     1,529,493  
     -  
     -